Elagolix + Add-Back Tx Reduces Heavy Menstrual Bleeding in Phase 3 Extension Study

By August 23, 2018

AbbVie plans to submit data from the phase 3 uterine fibroids program to the FDA sometime in 2019.

FDA Warning Ups Hysterectomy Complications for Uterine Fibroids

April 12, 2018

Among the women who underwent hysterectomy for uterine fibroids, there was a significant increase in major complications (from 1.9 to 2.4%; adjusted odds ratio, 1.23) and minor complications (from 2.7 to 3.3%; adjusted odds ratio, 1.21).

Positive Results for Elagolix in Second Phase 3 Uterine Fibroid Trial

By March 14, 2018

Results - measured by the alkaline hematin method - found that at 6 months those in the combination group had 76.2% (P<0.001) clinical response compared to the elagloix along group, in which only 10.1% had a clinical response.

First-in-Class Oral Tx for Uterine Fibroids One Step Closer to Approval

By October 10, 2017

Ulipristal acetate is a selective progesterone receptor modulator which acts directly on the progesterone receptors in the endometrium, uterine fibroids, and the pituitary gland.

Labeling Updated for IUDs Regarding Perforation Risk

By December 27, 2016

Data from a large, 1-year postmarketing safety study conducted in Europe found that lactation at the time of insertion of an IUD/IUS was associated with an increased risk of perforation.

Amerigen Approved for Generic Lysteda

By August 02, 2016

Amerigen announced that the Food and Drug Administration (FDA) has approved the Abbreviated New Drug Application (ANDA) for Tranexamic Acid Instant Release Tablets, the generic version of Ferring's Lysteda.

Young Cancer Patients at High Risk for Heavy Menstrual Bleeding

July 28, 2014

Adolescent girls undergoing treatment for cancer are at high risk for heavy menstrual bleeding, and gynecologic care is advised for careful management of this problem.

Treatment of Heavy Menstrual Bleeding Ups Quality of Life

June 11, 2014

Treatment of heavy menstrual bleeding is associated with improvements in health-related quality of life, with greater improvements for women with anemia at baseline.

ESHRE: Shift Work Influences Reproductive Outcomes

July 15, 2013

Mixed shift patterns is associated with increased rates of menstrual disruption, subfertility, and miscarriage.

For Chinese Women, Age of Menarche and Menopause Linked to Cardiovascular Risk

March 26, 2013

For Chinese women, the age of menarche and menopause is not related to the risk of diabetes, but does correlate with cardiovascular disease and osteoporosis.

Nonheme Iron Intake Linked to Reduced Risk of PMS

March 06, 2013

Intake of specific minerals seem to be associated with the risk of premenstrual syndrome (PMS), with high intake of nonheme iron linked to reduced risk of PMS.

Levonorgestrel-IUS Beats Usual Care for Menorrhagia

January 10, 2013

Compared with standard medical therapy, women with menorrhagia experience more effective, sustained physical and quality-of-life benefits from treatment with a levonorgestrel-releasing intrauterine system (IUS).

Watson Approved for Generic Lysteda

January 03, 2013

Watson announced that it has received FDA approval on its Abbreviated New Drug Application for Tranexamic Acid Tablets, the generic version of Ferring's Lysteda.

Respiratory Symptoms Vary Throughout Menstrual Cycle

December 03, 2012

The frequency of respiratory symptoms, including wheeze, shortness of breath, and cough, varies throughout the menstrual cycle.